The Role of B-Lymphocyte Stimulator in Neuroendocrine Tumors: Correlation with Tumor Differentiation, Disease status and the Presence of Metastases

Fabris, Martina; Tonutti, Elio; Panighel, Carolina; Blasone, Nadia; Visentini, Daniela; Pizzolitto, Stefano; Maglio, Giovanna De; Isola, Miriam; Curcio, Francesco; Grimaldi, Franco

doi:10.2174/1871522211108040306

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neuroendocrine tumors (NET) usually express numerous biologically active mediators. Serum levels of BAFF in NET patients (1.195 ± 0.568 ng/mL) are significantly higher compared to healthy controls (0.666 ± 0.240 ng/mL) [ 94 ]. Patients in disease progression (1.503 ± 0.637 ng/mL) and patients with metastases (1.391 ± 0.724 ng/mL) have higher serum BAFF levels compared to those with stable disease (0.906 ± 0.273 ng/mL) [ 94 ].…”

Section: Baff Levels Correlate With Disease Activity and Malignantmentioning

confidence: 99%

B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia

Řiháček

Vašků

Valík

et al. 2015

BioMed Research International

View full text Add to dashboard Cite

B-cell activating factor (BAFF) is a cytokine and adipokine of the TNF ligand superfamily. The main biological function of BAFF in maintaining the maturation of B-cells to plasma cells has recently made it a target of the first FDA-approved selective BAFF antibody, belimumab, for the therapy of systemic lupus erythematosus. Concomitantly, the role of BAFF in cancer has been a subject of research since its discovery. Here we review BAFF as a biomarker of malignant disease activity and prognostic factor in B-cell derived malignancies such as multiple myeloma. Moreover, anti-BAFF therapy seems to be a promising approach in treatment of B-cell derived leukemias/lymphomas. In nonhematologic solid tumors, BAFF may contribute to cancer progression by mechanisms both dependent on and independent of BAFF's proinflammatory role. We also describe ongoing research into the pathophysiological link between BAFF and cancer-related cachexia. BAFF has been shown to contribute to inflammation and insulin resistance which are known to worsen cancer cachexia syndrome. Taking all the above together, BAFF is emerging as a biomarker of several malignancies and a possible hallmark of cancer cachexia.

show abstract

Section: Baff Levels Correlate With Disease Activity and Malignantmentioning

confidence: 99%

B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia

Řiháček

Vašků

Valík

et al. 2015

BioMed Research International

View full text Add to dashboard Cite

show abstract

The BAFF-APRIL System in Cancer

Ullah

Mackay

2023

Cancers

View full text Add to dashboard Cite

B cell-activating factor (BAFF; also known as CD257, TNFSF13B, BLyS) and a proliferation-inducing ligand (APRIL; also known as CD256, TNFSF13) belong to the tumor necrosis factor (TNF) family. BAFF was initially discovered as a B-cell survival factor, whereas APRIL was first identified as a protein highly expressed in various cancers. These discoveries were followed by over two decades of extensive research effort, which identified overlapping signaling cascades between BAFF and APRIL, controlling immune homeostasis in health and driving pathogenesis in autoimmunity and cancer, the latter being the focus of this review. High levels of BAFF, APRIL, and their receptors have been detected in different cancers and found to be associated with disease severity and treatment response. Here, we have summarized the role of the BAFF-APRIL system in immune cell differentiation and immune tolerance and detailed its pathogenic functions in hematological and solid cancers. We also highlight the emerging therapeutics targeting the BAFF-APRIL system in different cancer types.

show abstract

The Role of B-Lymphocyte Stimulator in Neuroendocrine Tumors: Correlation with Tumor Differentiation, Disease status and the Presence of Metastases

Cited by 2 publications

References 0 publications

B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia

B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia

The BAFF-APRIL System in Cancer

Contact Info

Product

Resources

About